l‐Carnitine therapy improves right heart dysfunction through Cpt1‐dependent fatty acid oxidation
Open Access
- 1 July 2022
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (3) , e12107
Abstract
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy that ultimately leads to elevated pulmonary pressure and death by right ventricular (RV) failure, which occurs in part due to decreased fatty acid oxidation and cytotoxic lipid accumulation. In this study, we tested the hypothesis that decreased fatty acid oxidation and increased lipid accumulation in the failing RV is driven, in part, by a relative carnitine deficiency. We then tested whether supplementation of l‐carnitine can reverse lipotoxic RV failure through augmentation of fatty acid oxidation. In vivo in transgenic mice harboring a human BMPR2 mutation, l‐carnitine supplementation reversed RV failure by increasing RV cardiac output, improving RV ejection fraction, and decreasing RV lipid accumulation through increased PPARγ expression and augmented fatty acid oxidation of long chain fatty acids. These findings were confirmed in a second model of pulmonary artery banding‐induced RV dysfunction. In vitro, l‐carnitine supplementation selectively increased fatty acid oxidation in mitochondria and decreased lipid accumulation through a Cpt1‐dependent pathway. l‐Carnitine supplementation improves right ventricular contractility in the stressed RV through augmentation of fatty acid oxidation and decreases lipid accumulation. Correction of carnitine deficiency through l‐carnitine supplementation in PAH may reverse RV failure.Keywords
Funding Information
- National Institutes of Health (1K08HL153956, 3R01HL122417‐04S1, 5R01HL122417)
- Pulmonary Hypertension Association (Young Investigator Award)
This publication has 38 references indexed in Scilit:
- L-Carnitine preserves endothelial function in a lamb model of increased pulmonary blood flowPediatric Research, 2013
- Cardiac-Specific Deletion of Acetyl CoA Carboxylase 2 Prevents Metabolic Remodeling During Pressure-Overload HypertrophyCirculation Research, 2012
- A potential role for insulin resistance in experimental pulmonary hypertensionEuropean Respiratory Journal, 2012
- Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Unrecognized glucose intolerance is common in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2011
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertensionRespiratory Research, 2010
- PPARγ and the Pathobiology of Pulmonary Arterial Hypertension2009
- The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricleJournal of Molecular Medicine, 2009
- Disorders of carnitine transport and the carnitine cycleAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2006